文献速递间质性肺疾病肺结节与肺癌

淋巴管肌瘤病是肺癌的重要危险因素:日本大型队列研究

Lymphangioleiomyomatosis as a potent lung cancer risk factor: Insights from a Japanese large cohort study.
PubMed 文献 · Respirology · 2024-04-23

该研究基于日本单中心642例淋巴管肌瘤病(LAM)患者,对照日本癌症登记数据,发现LAM患者肺癌标准化发病比为13.6(95%CI 6.2-21.0,p=0.0008),中位随访5.13年期间13例(2.2%)诊断肺癌,提示LAM患者肺癌风险显著增加。

要点

  • LAM患者肺癌标准化发病比为13.6,风险显著高于一般人群。
  • 肺癌诊断中位年龄53岁,61.5%为从不吸烟者,均为女性。
  • 38.5%肺癌患者检出可靶向基因变异(EGFR 3例、ALK 1例、ERBB2 1例)。

核心结论

  • LAM患者肺癌风险显著增加,标准化发病比13.6(95%CI 6.2-21.0,p=0.0008)。

研究设计与样本

  • 日本单中心2001-2022年诊断的642例LAM患者(散发性557例,结节性硬化症相关80例,未分类5例),以日本癌症登记数据为参照人群计算相对风险。

主要发现

  • 中位随访5.13年,13例(2.2%)诊断肺癌,估计发病率为301.4例/10万人年。
  • 肺癌患者均为女性,61.5%为从不吸烟者,诊断中位年龄53岁,8例在LAM诊断后发生肺癌。
  • 可靶向基因变异检出率38.5%(EGFR 3例、ALK 1例、ERBB2 1例)。
  • 2例经二代测序分析未发现TSC基因功能缺失证据。

临床怎么用

  • 对LAM患者应提高肺癌监测意识,尤其关注女性及从不吸烟者。
  • 肺癌确诊后建议进行可靶向基因变异检测以指导治疗。

局限性

  • 单中心高流量中心研究,可能存在选择偏倚。
  • 仅2例进行二代测序分析,关于TSC基因功能的结论有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease associated with the functional tumour suppressor genes TSC1 and TSC2 and causes structural destruction in the lungs, which could potentially increase the risk of lung cancer. However, this relationship remains unclear because of the rarity of the disease. METHODS: We investigated the relative risk of developing lung cancer among patients diagnosed with LAM between 2001 and 2022 at a single high-volume centre in Japan, using data from the Japanese Cancer Registry as the reference population. Next-generation sequencing (NGS) was performed in cases where tumour samples were available. RESULTS: Among 642 patients diagnosed with LAM (sporadic LAM, n = 557; tuberous sclerosis complex-LAM, n = 80; unclassified, n = 5), 13 (2.2%) were diagnosed with lung cancer during a median follow-up period of 5.13 years. All patients were female, 61.5% were never smokers, and the median age at lung cancer diagnosis was 53 years. Eight patients developed lung cancer after LAM diagnosis. The estimated incidence of lung cancer was 301.4 cases per 100,000 person-years, and the standardized incidence ratio was 13.6 (95% confidence interval, 6.2-21.0; p = 0.0008). Actionable genetic alterations were identified in 38.5% of the patients (EGFR: 3, ALK: 1 and ERBB2: 1). No findings suggested loss of TSC gene function in the two patients analysed by NGS. CONCLUSION: Our study revealed that patients diagnosed with LAM had a significantly increased risk of lung cancer. Further research is warranted to clarify the carcinogenesis of lung cancer in patients with LAM.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Torasawa M, Shukuya T, Uemura K, et al. Lymphangioleiomyomatosis as a potent lung cancer risk factor: Insights from a Japanese large cohort study. Respirology. 2024. PMID: 38654512. doi:10.1111/resp.14724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。